Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tiaowei Chengqi Decoction (TWCQD) is a classic Traditional Chinese Medicine (TCM) formula originally documented in the *Shanghan Lun* (Treatise on Febrile Diseases). It is composed of three primary medicinal components: *Rheum palmatum* (Dahuang), *Glycyrrhiza uralensis* (Gancao), and *Natrii Sulfas* (Mangxiao). In modern clinical research, particularly at the Shanghai Ninth People's Hospital affiliated to Shanghai Jiao Tong University School of Medicine, TWCQD is investigated for the treatment of sepsis-induced gastrointestinal dysfunction (septic gut dysfunction). The formula works through a multi-target approach, primarily by inhibiting the systemic inflammatory response and protecting the intestinal mucosal barrier. Its active constituents, such as emodin and rhein from Rhubarb, are known to suppress pro-inflammatory cytokines like TNF-α and IL-6 via the TLR4/NF-κB signaling pathway. Additionally, the inclusion of sodium sulfate provides an osmotic laxative effect that promotes the clearance of endotoxins and restores gastrointestinal motility.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tiaowei chengqi decoction.